CLS Therapeutics is pioneering advancements in cancer treatment through its innovative approach to gene therapy, particularly with its lead candidate, CLS-014. This first-in-class therapy utilizes an adeno-associated vector to deliver a hyperactive variant of the human DNase I enzyme, which is designed to eliminate harmful circulating extracellular DNA from the bloodstream of cancer patients. By targeting this novel therapeutic pathway, CLS-014 aims to address significant unmet medical needs, starting with pancreatic cancer, and represents a transformative step in the fight against therapy-resistant tumors.

The company is also focused on leveraging its AAV-DNase platform technology to develop treatments for various solid tumors and other conditions, such as stroke and autoimmune diseases. CLS Therapeutics is committed to advancing the science of circulating nucleic acids and has assembled a team of experts in oncology and gene therapy to drive its research forward. Their collaborative efforts, including partnerships with other biopharmaceutical companies, aim to enhance the efficacy of existing cancer therapies and explore new avenues for treatment, thereby improving outcomes for patients facing challenging diagnoses.

United States

CLS Therapeutics is a biopharmaceutical firm that provides transformative gene therapy solutions for cancer patients.

CLS Therapeutics

Company Details